Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663086 | 0.96 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2KDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL13437237 | 0.80 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20995934 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29490161 | 0.78 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL24220376 | 0.78 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL13728543 | 0.75 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13402367 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL29312155 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL12868789 | 0.75 | P2RX4 (0.35) | ALDH1A1 | |
| SCHEMBL24229725 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | ALDH1A1 670/4885SMN1; SMN2 3550/4885KDM4E 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.